title: Inhibition of methyleugenol bioactivation by the herb-based constituent nevadensin and prediction of possible in vivo consequences using physiologically based kinetic modeling.
abstract: Methyleugenol (ME) occurs naturally in a variety of spices, herbs, including basil, and their essential oils. ME induces hepatomas in rodent bioassays following its conversion to a DNA reactive metabolite. In the present study, the basil constituent nevadensin was shown to be able to inhibit SULT-mediated DNA adduct formation in HepG2 cells exposed to the proximate carcinogen 1'-hydroxymethyleugenol in the presence of nevadensin. To investigate possible in vivo implications of SULT inhibition by nevadensin on ME bioactivation, the rat physiologically based kinetic (PBK) model developed in our previous work to describe the dose-dependent bioactivation and detoxification of ME in male rat was combined with the recently developed PBK model describing the dose-dependent kinetics of nevadensin in male rat. The resulting binary ME-nevadensin PBK model was used to predict the possible nevadensin mediated reduction in ME DNA adduct formation and resulting carcinogenicity at the doses of ME used by the NTP carcinogenicity study. Using these data an updated risk assessment using the Margin of Exposure (MOE) approach was performed. The results obtained point at a potential reduction of the cancer risk when rodents are orally exposed to ME within a relevant food matrix containing SULT inhibitors compared to exposure to pure ME.
authors.affiliation: Division of Toxicology, Wageningen University, Wageningen, The Netherlands.
authors.forename: Ala' A A
authors.initials: AA
authors.lastname: Al-Subeihi
authors.forename: Wasma
authors.initials: W
authors.lastname: Alhusainy
authors.forename: Alicia
authors.initials: A
authors.lastname: Paini
authors.forename: Ans
authors.initials: A
authors.lastname: Punt
authors.forename: Jacques
authors.initials: J
authors.lastname: Vervoort
authors.forename: Peter J
authors.initials: PJ
authors.lastname: van Bladeren
authors.forename: Ivonne M C M
authors.initials: IM
authors.lastname: Rietjens
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D001711:Biotransformation / Q000187:drug effects; D002273:Carcinogens / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics* / Q000633:toxicity; D018736:DNA Adducts / Q000037:antagonists & inhibitors / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D005054:Eugenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000633:toxicity; D005260:Female; D047309:Flavones / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D056945:Hep G2 Cells; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D008297:Male; D008954:Models, Biological; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D018570:Risk Assessment; D015238:Sulfotransferases / Q000037:antagonists & inhibitors / Q000378:metabolism; D014018:Tissue Distribution / Q000187:drug effects
chemical_list: D016588:Anticarcinogenic Agents; D002273:Carcinogens; D018736:DNA Adducts; D004791:Enzyme Inhibitors; D047309:Flavones; C023982:nevadensin; C005223:methyleugenol; D005054:Eugenol; C108731:1'-(hydroxymethyl)eugenol; D015238:Sulfotransferases
keywords: ((15)N(5)) ME-3′-N(2)-dG; (15)N(5)-2′-deoxyguanosine; (15)N(5)-2′dG; (15)N(5)-labeled N(2)-(trans-isomethyleugenol-3′-yl)-2′-deoxyguanosine; 1′-acetoxymethyleugenol; 1′-hydroxymethyleugenol; 1′-hydroxymethyleugenol glucuronide; 1′-oxomethyleugenol; 1′-sulfooxymethyleugenol; 1′ACME; 1′HME; 1′HMEG; 1′HMES; 1′OME; 2′-deoxyguanosine; 2′dG; 7-hydroxycoumarin; 7-hydroxycoumarin sulphate; 7HC; 7HCS; Bioactivation; DMSO; E-3′-N(2)-dG; FEMA; Flavor and Extract Manufacturers Association; GC; In vivo; Inhibition; K(i); L; LC; ME; ME-3′-N(2)-dG; MS; Methyleugenol; N(2)-(trans-isoestragol-3′-yl)-2′-deoxyguanosine; N(2)-(trans-isomethyleugenol-3′-yl)-2′-deoxyguanosine; NEV; NMWL; NTP; National Toxicology Program; Nevadensin; PBK; PCP; RT; SCF; SULT; Scientific Committee on Food; body weight; bw; dimethylsulfoxide; gas chromatography; hour; hr; inhibition constant; liquid chromatography; liver; mass spectrometry; methyleugenol; min; minute; nevadensin; nominal molecular weight limit; pentachlorophenol; physiologically based kinetic; retention time; sulfotransferase